Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Minjiang Chen, MD.
CONTACT
Mengzhao Wang, MD.
CONTACT
Lead
Peking Union Medical College Hospital
This is a multi-center study. The study plans to include a total of 27 advanced NSCLCs who had benefited from first-line immunotherapy over two years before disease progression. Participants will receive up to 17 cycles of ICI (anti-PD-1 or anti-PD-L1) monotherapy. Optional ICI monotherapy regimens include: Pembrolizumab 200mg every 3 weeks, or Tislelizumab 200mg every 3 weeks, or Camrelizumab 200mg every 3 weeks, or Toripalimab 240mg every 3 weeks. The outcomes including efficacy and safety will be examined. Additionally, peripheral blood samples will be collected before treatment, and at the 6th, 12th, and 24th weeks after treatment initiation to explore biomarkers for immunotherapy. Also it is highly recommended to collect pretreatment tumor tissue from patients.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
